Promega Corporation

Promega @cademy


Previous Webinars

Other Tools


Ask a Scientist

Ask Customer Service


Promega @cademy webinar: "Multiplexed In Vitro Viability and Cytotoxicity Methods for Strengthening Predictive Confidence and Improving Mechanistic Content"


The Promega @cademy provides a tailored programme of non-commercial live webinars, covering a wide range of scientific topics, from very basic concepts to highly technical research presentations.
The title of this webinar is: "Multiplexed In Vitro Viability and Cytotoxicity Methods for Strengthening Predictive Confidence and Improving Mechanistic Content".

Specialist Webinars
This is a
Specialist webinar, these webinars addresses more specialized topics and are useful for PhD students and senior scientists.



A central tenet of pharmacology is that all compounds have the capacity to induce toxicity due to dosage. These specific toxicity thresholds are inherently linked to cellular exposure period and cell-type susceptibility. Therefore, the practical implementation of any in vitro testing methodology is greatly dependent upon whether the study is designed to identify targeted cytotoxicity (oncology) or potential off-target toxicity (safety). Either way, the traditional experimental paradigm has been to triage data from large primary screening sets, and then examine the –œactives– with a battery of secondary assays in parallel. This talk will describe numerous same-well multiplex assay combinations which may obviate parallel assays because they provide immediate orthogonal or complementary measures useful for confirming cytotoxicity or flagging non-conforming points for additional study. For instance, viability and cytotoxicity assays can be added in meaningful combinations with genetic reporter or cytochrome p450 assays, early measures of cellular stress and apoptosis, or assays for specific obligate functional activities. This proposed multiplex paradigm is designed to streamline data acquisition efficiencies by reducing experimental effort, variability and adding mechanistic content.

This webinar was presented by Andrew Niles, Ph.D., R&D Scientist, Promega Corporation


This webinar was presented in the past so registration is not possible

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.